Researchers describe the first evidence linking prolactin inducible protein (PIP) to the immune system’s ability to recognize and destroy foreign cells, such as tumor cells. New research in prolactin inducible protein deficient mice that demonstrates the role of prolactin inducible protein in cell-mediated immunity and suggests that this immune regulatory function may be protective against breast cancer is presented in DNA and Cell Biology, a peer-reviewed journal.
Coauthors Olivia Ihedioha, Robert Shiu, Jude Uzonna, and Yvonne Myal, University of Manitoba, Winnipeg, Canada, describe the potential clinical implications of these findings, in which prolactin inducible protein could represent an effective new target for the development of novel immunotherapeutic agents.
“Breast cancers are among the most common tumors. prolactin inducible protein was observed to be selectively expressed by these cells,” says Carol Shoshkes Reiss, PhD, Editor-in-Chief of DNA and Cell Biology and Professor, Departments of Biology and Neural Science, and Global Public Health at New York University, NY. “The work from the Myal lab in this paper is exciting because of the immunoregulatory activity they describe. I hope it will lead to novel therapeutic approaches to this devastating disease.”
Citation: Prolactin-Inducible Protein: From Breast Cancer Biomarker to Immune Modulator—Novel Insights from Knockout Mice. Authors: Olivia C. Ihedioha, Robert P.C. Shiu, Jude E. Uzonna, and Yvonne Myal.
Journal: DNA and Cell Biology
Adapted from press release by Mary Ann Liebert, Inc., publishers